Edwin Liu
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 63 | 2025 | 290 | 10.680 |
Why?
| | Autoantibodies | 48 | 2024 | 1452 | 3.150 |
Why?
| | Transglutaminases | 28 | 2025 | 154 | 3.060 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 177 | 1.920 |
Why?
| | Diet, Gluten-Free | 11 | 2025 | 45 | 1.680 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 451 | 1.590 |
Why?
| | Autoimmunity | 23 | 2024 | 897 | 1.530 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 150 | 1.410 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3661 | 1.410 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2371 | 1.280 |
Why?
| | Peptide Fragments | 15 | 2008 | 690 | 1.250 |
Why?
| | Insulin | 24 | 2009 | 2394 | 1.250 |
Why?
| | Glutens | 10 | 2023 | 60 | 0.960 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 77 | 0.900 |
Why?
| | Islets of Langerhans | 17 | 2017 | 793 | 0.870 |
Why?
| | Rett Syndrome | 1 | 2024 | 40 | 0.850 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 226 | 0.750 |
Why?
| | Insulin Antibodies | 11 | 2013 | 100 | 0.750 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 207 | 0.740 |
Why?
| | Nutrition Therapy | 1 | 2020 | 37 | 0.650 |
Why?
| | Child | 45 | 2025 | 21760 | 0.630 |
Why?
| | Genetic Testing | 6 | 2015 | 455 | 0.630 |
Why?
| | Pyrrolidinones | 1 | 2019 | 29 | 0.620 |
Why?
| | Child, Preschool | 32 | 2025 | 10952 | 0.610 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 596 | 0.570 |
Why?
| | Patient Compliance | 2 | 2023 | 591 | 0.560 |
Why?
| | Down Syndrome | 2 | 2023 | 484 | 0.540 |
Why?
| | Anticonvulsants | 1 | 2019 | 214 | 0.530 |
Why?
| | Immunoglobulin A | 9 | 2025 | 210 | 0.530 |
Why?
| | Mass Screening | 8 | 2024 | 1295 | 0.520 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 193 | 0.480 |
Why?
| | Infant | 27 | 2025 | 9392 | 0.460 |
Why?
| | Humans | 86 | 2025 | 136965 | 0.460 |
Why?
| | Epilepsy | 1 | 2019 | 334 | 0.460 |
Why?
| | Intestinal Mucosa | 4 | 2025 | 621 | 0.450 |
Why?
| | Anaphylaxis | 3 | 2004 | 104 | 0.420 |
Why?
| | Caregivers | 1 | 2022 | 903 | 0.420 |
Why?
| | Poly I-C | 4 | 2008 | 63 | 0.410 |
Why?
| | Depression | 2 | 2022 | 1454 | 0.400 |
Why?
| | Female | 58 | 2025 | 73002 | 0.390 |
Why?
| | Adolescent | 25 | 2025 | 21471 | 0.390 |
Why?
| | Gliadin | 3 | 2018 | 13 | 0.380 |
Why?
| | Radioimmunoassay | 3 | 2016 | 169 | 0.360 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2142 | 0.360 |
Why?
| | Prospective Studies | 21 | 2024 | 7512 | 0.360 |
Why?
| | Male | 49 | 2025 | 67386 | 0.360 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5048 | 0.350 |
Why?
| | Telemedicine | 1 | 2020 | 863 | 0.350 |
Why?
| | Jejunum | 1 | 2011 | 33 | 0.340 |
Why?
| | Biopsy | 11 | 2025 | 1083 | 0.340 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 229 | 0.330 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 94 | 0.320 |
Why?
| | Quality of Life | 5 | 2024 | 2899 | 0.310 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1923 | 0.310 |
Why?
| | Nutritionists | 2 | 2020 | 19 | 0.310 |
Why?
| | Risk Factors | 17 | 2024 | 10363 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 65 | 0.300 |
Why?
| | Luminescent Measurements | 2 | 2020 | 73 | 0.300 |
Why?
| | Dietary Proteins | 2 | 2019 | 134 | 0.280 |
Why?
| | Laboratories | 1 | 2009 | 108 | 0.280 |
Why?
| | Mice | 32 | 2013 | 17705 | 0.270 |
Why?
| | Interferon-alpha | 2 | 2005 | 199 | 0.270 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.260 |
Why?
| | Poly A-U | 1 | 2006 | 4 | 0.260 |
Why?
| | Immune Tolerance | 4 | 2013 | 363 | 0.250 |
Why?
| | Europe | 6 | 2017 | 403 | 0.250 |
Why?
| | T-Lymphocytes | 7 | 2008 | 1975 | 0.250 |
Why?
| | Serologic Tests | 4 | 2021 | 53 | 0.240 |
Why?
| | Time Factors | 10 | 2025 | 6786 | 0.240 |
Why?
| | HLA Antigens | 5 | 2019 | 238 | 0.230 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.220 |
Why?
| | Dyspepsia | 1 | 2024 | 10 | 0.220 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 1999 | 0.220 |
Why?
| | CD4 Antigens | 2 | 2003 | 140 | 0.210 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 850 | 0.210 |
Why?
| | Antibodies | 3 | 2014 | 406 | 0.210 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 52 | 0.210 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 64 | 0.210 |
Why?
| | Animals | 34 | 2015 | 36882 | 0.210 |
Why?
| | Genotype | 7 | 2019 | 1872 | 0.210 |
Why?
| | Autoantigens | 6 | 2009 | 421 | 0.200 |
Why?
| | Peptides | 3 | 2018 | 975 | 0.200 |
Why?
| | Abdominal Pain | 1 | 2024 | 146 | 0.200 |
Why?
| | Endosonography | 1 | 2024 | 152 | 0.200 |
Why?
| | Diet | 4 | 2019 | 1279 | 0.200 |
Why?
| | Biomarkers | 7 | 2025 | 4095 | 0.190 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1256 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 716 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 541 | 0.180 |
Why?
| | Ileal Diseases | 1 | 2001 | 12 | 0.180 |
Why?
| | Catheterization | 2 | 2001 | 174 | 0.180 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 26 | 0.180 |
Why?
| | Colonic Diseases | 1 | 2001 | 33 | 0.180 |
Why?
| | Comorbidity | 2 | 2024 | 1626 | 0.180 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1251 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2156 | 0.170 |
Why?
| | Dietetics | 1 | 2020 | 27 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1083 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 549 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 90 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2024 | 573 | 0.160 |
Why?
| | Infant, Newborn | 8 | 2019 | 6051 | 0.160 |
Why?
| | Incidence | 5 | 2022 | 2793 | 0.160 |
Why?
| | Vaccines | 1 | 2004 | 400 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 86 | 0.150 |
Why?
| | Probiotics | 1 | 2019 | 55 | 0.150 |
Why?
| | Duodenum | 3 | 2023 | 76 | 0.150 |
Why?
| | Immunization | 4 | 2007 | 404 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2732 | 0.150 |
Why?
| | Risk | 3 | 2019 | 901 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1056 | 0.150 |
Why?
| | Risk Assessment | 8 | 2020 | 3446 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 220 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 350 | 0.140 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1412 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 1052 | 0.130 |
Why?
| | United States | 9 | 2025 | 14945 | 0.130 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 15 | 0.130 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 44 | 0.130 |
Why?
| | Parents | 2 | 2024 | 1412 | 0.130 |
Why?
| | Feces | 1 | 2019 | 480 | 0.130 |
Why?
| | Cesarean Section | 1 | 2018 | 184 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 15536 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 68 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 182 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5530 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 90 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5812 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2020 | 767 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4276 | 0.120 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 85 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 76 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2021 | 892 | 0.110 |
Why?
| | Case-Control Studies | 6 | 2019 | 3556 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 535 | 0.110 |
Why?
| | Homozygote | 1 | 2014 | 203 | 0.110 |
Why?
| | ROC Curve | 3 | 2013 | 554 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 428 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 2999 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 203 | 0.100 |
Why?
| | Child Development | 1 | 2017 | 466 | 0.100 |
Why?
| | Clonal Anergy | 1 | 2013 | 52 | 0.100 |
Why?
| | Young Adult | 5 | 2024 | 13218 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Cohort Studies | 6 | 2025 | 5688 | 0.100 |
Why?
| | Mice, SCID | 4 | 2008 | 368 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2020 | 994 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 157 | 0.100 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 76 | 0.100 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2139 | 0.090 |
Why?
| | Protein Precursors | 2 | 2003 | 133 | 0.090 |
Why?
| | Sweden | 3 | 2017 | 101 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 868 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 433 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1630 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 488 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4542 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2024 | 10664 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 305 | 0.090 |
Why?
| | Adenoviridae | 2 | 2019 | 194 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1784 | 0.080 |
Why?
| | Proinsulin | 3 | 2008 | 52 | 0.080 |
Why?
| | Plant Proteins | 1 | 2011 | 114 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 323 | 0.080 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 5733 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 681 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3266 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 35 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 907 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1365 | 0.080 |
Why?
| | Radioligand Assay | 1 | 2009 | 37 | 0.080 |
Why?
| | Bilirubin | 2 | 2008 | 88 | 0.080 |
Why?
| | Prediabetic State | 3 | 2009 | 249 | 0.080 |
Why?
| | Ammonia | 2 | 2008 | 62 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2013 | 420 | 0.080 |
Why?
| | Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2809 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.070 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 12 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 158 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 514 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 185 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2708 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 348 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 31 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 58 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 106 | 0.070 |
Why?
| | Adult | 8 | 2023 | 37715 | 0.070 |
Why?
| | Self-Help Groups | 1 | 2007 | 36 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 347 | 0.060 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 198 | 0.060 |
Why?
| | Blood Glucose | 3 | 2006 | 2184 | 0.060 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 782 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 135 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 303 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 294 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 39 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2066 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 155 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2015 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1061 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 3258 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 24 | 0.060 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 9 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.060 |
Why?
| | CD3 Complex | 1 | 2024 | 104 | 0.050 |
Why?
| | Survival Rate | 2 | 2007 | 1882 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2900 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 845 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 96 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 56 | 0.050 |
Why?
| | Canada | 1 | 2025 | 407 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 76 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 166 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 139 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 236 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 346 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 189 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 556 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 476 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 20 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 28 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 8 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1470 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2574 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 832 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 35 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 42 | 0.050 |
Why?
| | Immunotherapy | 1 | 2007 | 627 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 365 | 0.050 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 71 | 0.050 |
Why?
| | Oligopeptides | 1 | 2003 | 269 | 0.050 |
Why?
| | Paracentesis | 1 | 2001 | 14 | 0.050 |
Why?
| | Gastroschisis | 1 | 2001 | 29 | 0.040 |
Why?
| | Ascites | 1 | 2001 | 46 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 8 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 152 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 399 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 3931 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 721 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1480 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1278 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 89 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 836 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1700 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 288 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 83 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 250 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 309 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1730 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 73 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1543 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2851 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5544 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 178 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 125 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 487 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 270 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 169 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 457 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 615 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 42 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1460 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 797 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3148 | 0.030 |
Why?
| | China | 1 | 2016 | 213 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 749 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 243 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1705 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 506 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 622 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 194 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2019 | 559 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 94 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 198 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 119 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1849 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1428 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 86 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 505 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 300 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1706 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 354 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2168 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1310 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 783 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 131 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 384 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 240 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 735 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 165 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2416 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2060 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 583 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 758 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 415 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 586 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 54 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 6736 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 388 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 373 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 14 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 29 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 13 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2622 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2048 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 33 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 83 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1134 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 22 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 263 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 235 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 358 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 16 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 38 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 89 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 182 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 335 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 287 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4136 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 24 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 631 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 48 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 165 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 98 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 64 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2855 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 522 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 74 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2553 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 527 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 38 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1774 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 105 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 230 | 0.010 |
Why?
| | Needles | 1 | 2001 | 60 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 171 | 0.010 |
Why?
| | Safety | 1 | 2001 | 343 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 885 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 819 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 33226 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3023 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 3975 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|